Hemochromatosis
22
0
1
16
Key Insights
Highlights
Success Rate
94% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
4.5%
1 terminated out of 22 trials
94.1%
+7.6% vs benchmark
14%
3 trials in Phase 3/4
6%
1 of 16 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 16 completed trials
Clinical Trials (22)
Treatment of Hemochromatosis
Repeatability and Reproducibility of Multiparametric MRI
Confounder-Corrected Quantitative MRI Biomarker of Hepatic Iron Content
MRI QSM Imaging for Iron Overload
Treatment of Iron Overload With Deferasirox (Exjade) in Hereditary Hemochromatosis and Myelodysplastic Syndrome
"Iron Overload and Endocrinological Diseases"
Deferoxamine for the Treatment of Hemochromatosis
Research Network for Neonatal Diseases Induced by Tissular Fetomaternal Alloimmunization
Study of the Cellular Diffusion of Tacrolimus Across the Membrane of Mononuclear Cells
Oral Nifedipine to Treat Iron Overload
Hemochromatosis and Iron Overload Screening Study (HEIRS)
Statistical Basis for Hemochromatosis Screening
Evaluation of a New MR Pulse Sequence to Quantify Liver Iron Concentration
Hemochromatosis--Genetic Prevalence and Penetrance
Evaluation of Subcutaneous Desferrioxamine as Treatment for Transfusional Hemochromatosis
Stroke With Transfusions Changing to Hydroxyurea
Study With Deferiprone and/or Desferrioxamine in Iron Overloaded Patients
Proton Pump Inhibitors in the Prevention of Iron Reaccumulation in Patient With Hereditary Hemochromatosis
Study Using Deferiprone Alone or in Combination With Desferrioxamine in Iron Overloaded Transfusion-dependent Patients
Haemochromatosis:Phlebotomy Versus Erythrocytapheresis Therapy